← PureTech Health plc (PRTC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
PureTech Health plc (PRTC)
Biotechnology · market cap $4.2B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
PureTech Health plc (PRTC) is a biotechnology company with 56 employees and a market cap of approximately $4.21B, trading at ~$17.42. Its pipeline includes three Phase 2 assets: Pirfenidone for Idiopathic Pulmonary Fibrosis, LYT-300 studied in healthy volunteers, and LYT-200 in metastatic cancer. No upcoming catalysts are currently calendared and key financial metrics — cash position, runway, and dilution history — are not disclosed in the available facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Pirfenidone | Phase 2 | Idiopathic Pulmonary Fibrosis |
| LYT-300 | Phase 2 | Healthy Volunteers |
| LYT-200 | Phase 2 | Metastatic Cancer |
| Deupirfenidone | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF) |
Price & technical context
3-month
-3.7%
6-month
+8.7%
12-month
+3.0%
52-wk range
$14.50–$19.84
vs 50-day MA
+3.5%
vs 200-day MA
+1.0%
Realized vol
46.8%
Max drawdown
-59.1%
Daily closes through 2026-05-20. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PRTC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.